Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis in a randomized, placebo controlled, combined first-in-man and proof of concept study

Boumans, M; Houbiers, J; Verschueren, Patrick; Ishikura, A; Westhovens, Rene; Brouwer, E; Rojkovich, B; Kelly, S; Den Adel, M; Isaacs, J; Gomez-Reino, J; Holtkamp, G; Gerlag, D; Tak, P

Arthritis and Rheumatism

Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis in a randomized, placebo controlled, combined first-in-man and proof of concept study

Author:

Boumans, M

Houbiers, J ; Verschueren, Patrick ; Ishikura, A ; Westhovens, Rene ; Brouwer, E ; Rojkovich, B ; Kelly, S ; Den Adel, M ; Isaacs, J ; Gomez-Reino, J ; Holtkamp, G ; Gerlag, D ; Tak, P

Arthritis and Rheumatism Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis in a randomized, placebo controlled, combined first-in-man and proof of concept study

Author:

Arthritis and Rheumatism

Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis in a randomized, placebo controlled, combined first-in-man and proof of concept study